Armed Cell Acquires Lakefront Preclinical CAR T Portfolio
Lakefront Biotherapeutics completed the sale of its preclinical multi-targeting and armed CAR-T portfolio to newly formed Armed Cell Therapeutics. Lakefront receives €8 million upfront, may earn up to $230 million in milestones and retains…
